Gilead Sciences, Inc. (GILD)

NasdaqGS - NasdaqGS Real-time price. Currency in USD

Add to watchlist

83.16

+2.22

(+2.74%)

At close: 04:00PM EDT

82.54

+0.15

(+0.18%)

Pre-market:

04:50AM EDT

Loading interactive chart…

Investor's Business Daily
Gilead Sciences Pops On A New $4 Billion Opportunity In HIV Prevention
Gilead stock popped Thursday after the biotech giant said its twice-yearly shot prevented 99.9% of HIV infections in a study.
Barrons.com
Gilead Unveils More Positive Data on HIV Prevention Shot
The trial is the second successful result for lenacapavir following a study in which the shot prevented HIV in all of the more than 2,000 women and girls who received the shot.
Investing.com
Gilead says HIV prevention injection reduced cases by 96%, sending shares higher
Investing.com -- Shares in Gilead Sciences (NASDAQ:GILD) rose in early US trading on Thursday after the pharmaceutical group announced that a Phase 3 trial of its HIV drug reduced infections of the disease.